Company intelligence / Profile preview
Clasp Therapeutics
Cambridge, Massachusetts, United Statesclasptx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Clasp Therapeutics has launched with $150 million in funding to develop next-generation, highly specific T cell engagers that target tumor-specific mutations. The company’s approach aims to improve efficacy and safety over existing TCEs by focusing on truly tumor-specific antigens, reducing off-tumor toxicity. Clinical results are not yet available as the programs are preclinical.
- Therapeutic areas
- Oncology
- Modalities
- T cell engagers (TCEs)Bispecific antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
No major pharmaceutical or biotech partnerships announced as of launch.
Beyond the preview
Go deeper on Clasp Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clasp Therapeutics.